# Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

> **NCT03492671** · PHASE2 · RECRUITING · sponsor: **Loma Linda University** · enrollment: 30 (estimated)

## Conditions studied

- Pancreas Adenocarcinoma
- Resectable Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine 1000 mg
- **DRUG:** nab-paclitaxel
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT03492671
- **Lead sponsor:** Loma Linda University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-07-17
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03492671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03492671, "Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03492671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*